@techreport{OPUS4-35963,
  title     = {Platelets - Molecular, cellular and systemic functions in health and disease},
  editor    = {Nieswandt, Bernhard},
  organization    = {Collaborative Research Centre/Transregio 240},
  doi       = {10.25972/OPUS-35963},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-359636},
  pages     = {25},
  year      = {2024},
  abstract  = {Besides their central role in haemostasis and thrombosis, platelets are increasingly recognised as versatile effector cells in inflammation, the innate and adaptive immune response, extracellular matrix reorganisation and fibrosis, maintenance of barrier and organ integrity, and host response to pathogens. These platelet functions, referred to as thrombo-inflammation and immunothrombosis, have gained major attention in the COVID-19 pandemic, where patients develop an inflammatory disease state with severe and life-threatening thromboembolic complications. In the CRC/TR 240, a highly interdisciplinary team of basic, translational and clinical scientists explored these emerging roles of platelets with the aim to develop novel treatment concepts for cardiovascular disorders and beyond. We have i) unravelled mechanisms leading to life-threatening thromboembolic complica-tions following vaccination against SARS-CoV-2 with adenoviral vector-based vaccines, ii) identified unrecognised functions of platelet receptors and their regulation, offering new potential targets for pharmacological intervention and iii) developed new methodology to study the biology of megakar-yocytes (MKs), the precursor cells of platelets in the bone marrow, which lay the foundation for the modulation of platelet biogenesis and function. The projects of the CRC/TR 240 built on the unique expertise of our research network and focussed on the following complementary fields: (A) Cell bi-ology of megakaryocytes and platelets and (B) Platelets as regulators and effectors in disease. To achieve this aim, we followed a comprehensive approach starting out from in vitro systems and animal models to clinical research with large prospective patient cohorts and data-/biobanking. Despite the comparably short funding period the CRC/TR 240 discovered basic new mechanisms of platelet biogenesis, signal transduction and effector function and identified potential MK/platelet-specific molecular targets for diagnosis and therapy of thrombotic, haemorrhagic and thrombo-inflammatory disease states.},
  subject      = {Thrombozyt},
  language  = {en}
}
@article{OPUS4-31266,
  title     = {Combination of inclusive and differential t(t)over-bar charge asymmetry measurements using ATLAS and CMS data at root S=7 and 8 TeV},
  series = {Journal of High Energy Physics},
  volume    = {33},
  journal   = {Journal of High Energy Physics},
  number    = {4},
  organization    = {The ATLAS collaboration and the CMS collaboration},
  doi       = {10.1007/JHEP04(2018)033},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-312669},
  pages     = {1-67},
  year      = {2018},
  abstract  = {This paper presents combinations of inclusive and differential measurements of the charge asymmetry (A(C)) in top quark pair (t(t)over-bar) events with a lepton+jets signature by the ATLAS and CMS Collaborations, using data from LHC proton-proton collisions at centre-of-mass energies of 7 and 8 TeV. The data correspond to integrated luminosities of about 5 and 20 fb(-1) for each experiment, respectively. The resulting combined LHC measurements of the inclusive charge asymmetry are A(C)(LHC7) = 0.005 +/- 0.007 (stat) +/- 0.006 (syst) at 7 TeV and A(C)(LHC8) = 0.0055 +/- 0.0023 (stat) +/- 0.0025 (syst) at 8 TeV. These values, as well as the combination of A(C) measurements as a function of the invariant mass of the t(t)over-bar system at 8 TeV, are consistent with the respective standard model predictions.},
  language  = {en}
}